Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
Authors' conclusion
This analysis provides additional clinical results that may positively balance the benefit/risk assessment of SGLT inhibition use in T1D.
Study context
- Population
- Adults with T1D in the inTandem trials, treated for 24 weeks
- Participants
- 2,980 adults
- Comparison
- Sotagliflozin (SOTA) vs placebo
- Primary endpoint
- Predicted cumulative risk of CVD and kidney failure (Steno T1 Risk Engine)
Methodological detailsparticipant-level data, Steno T1 Risk Engine
- Participant-level data
- Steno T1 Risk Engine
Primary result
As reported in the abstract
Predicted CVD and kidney failure risk (Steno T1 Risk Engine), relative change vs placebo · 24 weeks
Each group vs placeboEstimate (95% CI)P value
SOTA 200 and 400 mg pooled
relative change, mean (predicted 5-year CVD risk) −6.6 %(−7.9 to −5.3)
P < 0.0001SOTA 200 and 400 mg pooled
relative change, mean (predicted 10-year CVD risk) −6.4 %(−7.6 to −5.1)
P < 0.0001- Predicted 5-year ESKD risk: significant reduction, relative change
- −5.0 (−7.6, −2.3) % (p = 0.0003)
Further findings
Individual doses and subgroup with BMI ≥ 27 kg/m²
- Similar results with the individual doses and in participants with BMI ≥ 27 kg/m²
Original publication
Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes. Diabetes Obes Metab. Published 20 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →